Annette Marcantonio
Corporate Officer/Principal presso JASPER THERAPEUTICS, INC.
Profilo
Annette Marcantonio is currently the Vice President-Clinical Operations at Jasper Therapeutics, Inc. She previously held the same position at Aimmune Therapeutics, Inc. from 2016 to 2020 and at Neurogastrx, Inc. from 2021 to 2022.
Ms. Marcantonio completed her undergraduate degree at Loyola Marymount University and holds an MBA from the University of Phoenix.
Posizioni attive di Annette Marcantonio
| Società | Posizione | Inizio |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Corporate Officer/Principal | 02/08/2023 |
Precedenti posizioni note di Annette Marcantonio
| Società | Posizione | Fine |
|---|---|---|
Neurogastrx, Inc.
 Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Corporate Officer/Principal | 01/12/2022 |
| AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2020 |
Formazione di Annette Marcantonio
| Loyola Marymount University | Undergraduate Degree |
| University of Phoenix | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| JASPER THERAPEUTICS, INC. | Finance |
| Aziende private | 2 |
|---|---|
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Neurogastrx, Inc.
Neurogastrx, Inc. BiotechnologyHealth Technology Neurogastrx, Inc. operates as a venture-stage biopharmaceutical company. The firm develops biopharmaceutical products for the treatment of gastrointestinal disorders. It offers NG101, a product for the treatment of gastroparesis. The company was founded by Cyril De Colle and Pankaj Jay Pasricha and is headquartered in Campbell, CA. | Health Technology |
- Borsa valori
- Insiders
- Annette Marcantonio
